Sanofi India Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Sanofi IndiaDie Umsatzerlöse und Gewinne des Unternehmens werden voraussichtlich um 2.5% bzw. 2.6% pro Jahr zurückgehen. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 32.9% betragen.

Wichtige Informationen

-2.6%

Wachstumsrate der Gewinne

12.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.9%
Wachstumsrate der Einnahmen	-2.5%
Zukünftige Eigenkapitalrendite	32.9%
Analystenabdeckung	Low
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Sanofi India Limited (NSE:SANOFI)

Dec 21

Is Sanofi India (NSE:SANOFI) A Risky Investment?

May 26

Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?

May 10

Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490

Apr 02

Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490

Feb 25

Estimating The Fair Value Of Sanofi India Limited (NSE:SANOFI)

Dec 10

Gewinn- und Umsatzwachstumsprognosen

NSEI:SANOFI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	25,014	4,492	2,953	N/A	2
12/31/2025	23,057	4,215	3,182	N/A	3
12/31/2024	20,068	3,494	3,478	N/A	2
9/30/2024	28,225	5,304	N/A	N/A	N/A
6/30/2024	27,893	5,288	2,873	3,315	N/A
3/31/2024	28,470	5,491	N/A	N/A	N/A
12/31/2023	28,511	6,029	1,961	2,304	N/A
9/30/2023	28,291	5,961	N/A	N/A	N/A
6/30/2023	28,064	5,751	5,090	5,411	N/A
3/31/2023	27,996	5,726	N/A	N/A	N/A
12/31/2022	27,701	6,206	3,765	3,987	N/A
9/30/2022	27,861	5,801	N/A	N/A	N/A
6/30/2022	28,487	9,790	1,447	1,633	N/A
3/31/2022	29,385	10,369	N/A	N/A	N/A
12/31/2021	29,566	9,444	5,358	5,588	N/A
9/30/2021	29,890	9,770	N/A	N/A	N/A
6/30/2021	29,211	5,801	8,106	8,294	N/A
3/31/2021	28,425	5,381	N/A	N/A	N/A
12/31/2020	29,019	4,776	5,697	6,111	N/A
9/30/2020	30,079	4,519	N/A	N/A	N/A
6/30/2020	31,004	4,456	5,127	5,765	N/A
3/31/2020	31,378	4,067	N/A	N/A	N/A
12/31/2019	30,706	4,142	3,365	4,123	N/A
9/30/2019	29,707	3,962	N/A	N/A	N/A
6/30/2019	29,354	3,888	N/A	N/A	N/A
3/31/2019	28,704	3,910	N/A	N/A	N/A
12/31/2018	27,708	3,806	3,147	3,739	N/A
9/30/2018	26,870	3,773	N/A	N/A	N/A
6/30/2018	26,107	3,744	N/A	N/A	N/A
3/31/2018	25,284	3,485	N/A	N/A	N/A
12/31/2017	24,636	3,260	N/A	4,351	N/A
9/30/2017	23,747	2,953	N/A	N/A	N/A
6/30/2017	23,454	2,619	N/A	N/A	N/A
3/31/2017	23,650	2,744	N/A	N/A	N/A
12/31/2016	23,668	3,042	N/A	3,221	N/A
9/30/2016	23,452	2,989	N/A	N/A	N/A
6/30/2016	23,068	2,909	N/A	N/A	N/A
3/31/2016	22,486	2,699	N/A	N/A	N/A
12/31/2015	21,931	2,377	N/A	2,132	N/A
9/30/2015	21,363	2,111	N/A	N/A	N/A
6/30/2015	20,654	2,005	N/A	N/A	N/A
3/31/2015	20,215	1,938	N/A	N/A	N/A
12/31/2014	19,775	1,971	N/A	2,650	N/A
9/30/2014	19,539	2,384	N/A	N/A	N/A
6/30/2014	19,364	2,534	N/A	N/A	N/A
3/31/2014	18,657	2,471	N/A	N/A	N/A
12/31/2013	18,089	2,398	N/A	2,726	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SANOFIFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-2.6% pro Jahr).

Ertrag vs. Markt: SANOFIFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-2.6% pro Jahr).

Hohe Wachstumserträge: SANOFIFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: SANOFIDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-2.5% pro Jahr).

Hohe Wachstumseinnahmen: SANOFIDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-2.5% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SANOFIDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (32.9%)

Sanofi India Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 9.1% to ₹8,501

Price target increased by 8.8% to ₹9,371

Price target increased by 12% to ₹8,392

Price target increased by 7.6% to ₹6,996

Price target decreased by 7.9% to ₹6,604

Price target decreased by 8.5% to ₹6,986

Recent updates

Third quarter 2024 earnings released: EPS: ₹35.69 (vs ₹65.95 in 3Q 2023)

Sanofi India Limited to Report Q3, 2024 Results on Nov 07, 2024

Sanofi India Limited Announces Resignation of Radhika Shah as Head of Legal and Company Secretary

Sanofi India Limited Announces Cessation of Cyrus Aibara as Senior Director Diabetes

Price target decreased by 9.1% to ₹8,501

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: ₹29.61 (vs ₹53.37 in 2Q 2023)

Sanofi India Limited Announces Resignation of Nitin Joshi, Head - Supply Chain, Effective 31 July 2024

Sanofi India Limited to Report Q2, 2024 Results on Jul 26, 2024

Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024

Less than half of directors are independent

Sanofi India Limited Appoints N. Suresh Babu as Sales & Customer Engagement Head Diabetes, Effective July 1, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Sanofi India Limited's (NSE:SANOFI) 25% Share Price Surge Not Quite Adding Up

Sanofi India Limited Announces Resignation of Shalini Menon as General Medicines Medical Head and India Medical Lead

First quarter 2024 earnings released: EPS: ₹59.31 (vs ₹82.67 in 1Q 2023)

Upcoming dividend of ₹117 per share

Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00

Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility

Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00

Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee

Sanofi India (NSE:SANOFI) Is Due To Pay A Dividend Of ₹117.00

Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director, Member of the Nomination and Remuneration Committee

Sanofi India's (NSE:SANOFI) Dividend Will Be ₹117.00

Final dividend of ₹117 announced

Upcoming dividend of ₹50.00 per share

Price target increased by 8.8% to ₹9,371

Full year 2023 earnings released: EPS: ₹262 (vs ₹269 in FY 2022)

Sanofi India Limited, Annual General Meeting, May 14, 2024

Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024

Sanofi India Limited to Report Q4, 2023 Results on Feb 23, 2024

Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024

Risks To Shareholder Returns Are Elevated At These Prices For Sanofi India Limited (NSE:SANOFI)

Price target increased by 12% to ₹8,392

Third quarter 2023 earnings released: EPS: ₹65.95 (vs ₹56.84 in 3Q 2022)

Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Whole-Time Director

Sanofi India Limited to Report Q3, 2023 Results on Nov 08, 2023

Sanofi India Limited Appoints Surabhi Kaul as India People Director and Will Be Part of the Senior Management Personnel

Less than half of directors are independent

Sanofi India Limited Announces Executive Changes

Sanofi India Limited Announces Resignation of Vinita Korti Patil as Senior Legal Director - South Asia, Effective 7 December 2023

Second quarter 2023 earnings released: EPS: ₹53.37 (vs ₹52.28 in 2Q 2022)

Sanofi India Limited Announces Resignation of Gaurav Bahadur as People Director

Less than half of directors are independent

Sanofi India Limited to Report Q2, 2023 Results on Aug 10, 2023

Sanofi India Limited Announces Resignation of Annapurna Das as Non-Executive Director and Member of the Audit Committee, Effective 31 July 2023

Is Sanofi India (NSE:SANOFI) A Risky Investment?

Price target increased by 7.6% to ₹6,996

Full year 2022 earnings released: EPS: ₹269 (vs ₹410 in FY 2021)

Price target decreased by 7.9% to ₹6,604

Price target decreased by 8.5% to ₹6,986

Sanofi India Limited to Report Q4, 2022 Results on Feb 23, 2023

High number of new directors

Third quarter 2022 earnings released: EPS: ₹56.84 (vs ₹230 in 3Q 2021)

Sanofi India Limited Announces Change in Directorate

Sanofi India Limited to Report Q3, 2022 Results on Nov 03, 2022

Upcoming dividend of ₹193 per share

Price target decreased to ₹7,800

Second quarter 2022 earnings released: EPS: ₹52.28 (vs ₹77.42 in 2Q 2021)

Sanofi India Limited Approves One-Time Special Interim Dividend, Payable on August 22, 2022

Sanofi India Limited to Report Q2, 2022 Results on Jul 26, 2022

Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?

First quarter 2022 earnings released: EPS: ₹104 (vs ₹63.35 in 1Q 2021)

Less than half of directors are independent

Sanofi India Appoints Rodolfo Hrosz as Managing Director

Sanofi India Limited to Report Q1, 2022 Results on Apr 26, 2022

Upcoming dividend of ₹490 per share

Full year 2021 earnings released: EPS: ₹410 (vs ₹207 in FY 2020)